Aliases & Classifications for Prostate Disease

Summaries for Prostate Disease

MedlinePlus : 40 The prostate is a gland in men. It helps make semen, the fluid that contains sperm. The prostate surrounds the tube that carries urine away from the bladder and out of the body. A young man's prostate is about the size of a walnut. It slowly grows larger with age. If it gets too large, it can cause problems. This is very common after age 50. The older men get, the more likely they are to have prostate trouble. Some common problems are Prostatitis - inflammation, usually caused by bacteria Enlarged prostate (BPH), or benign prostatic hyperplasia - a common problem in older men which may cause dribbling after urination or a need to go often, especially at night Prostate cancer - a common cancer that responds best to treatment when detected early NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Prostate Disease, also known as prostatic diseases, is related to prostatic hypertrophy and prostatic hyperplasia, benign, and has symptoms including equilibration disorder, prostatism and tremor. An important gene associated with Prostate Disease is KLK3 (Kallikrein Related Peptidase 3), and among its related pathways/superpathways are Endometrial cancer and Glucose / Energy Metabolism. The drugs Iodine and Povidone have been mentioned in the context of this disorder. Affiliated tissues include prostate, bone and breast, and related phenotypes are homeostasis/metabolism and endocrine/exocrine gland

Wikipedia : 72 The prostate (from Ancient Greek προστάτης, prostates, literally \"one who stands before\",... more...

Related Diseases for Prostate Disease

Diseases related to Prostate Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 59)
# Related Disease Score Top Affiliating Genes
1 prostatic hypertrophy 29.3 AR CYP19A1 KLK3
2 prostatic hyperplasia, benign 28.1 AR CYP19A1 FOLH1 KLK3 SERPINA3 SRD5A2
3 prostate cancer 27.0 AKR1C3 AMACR AR CYP19A1 FOLH1 KLK3
4 prostatitis 11.0
5 nodular prostate 10.4 AR KLK3
6 5-alpha reductase deficiency 10.4 SRD5A1 SRD5A2
7 villous adenoma 10.3 FOLH1 KLK3
8 prostatic adenoma 10.3 AR KLK3 SRD5A1
9 hermaphroditism 10.3 AR SRD5A2
10 transsexualism 10.2 AR CYP19A1
11 penis agenesis 10.2 AR SRD5A1 SRD5A2
12 gender identity disorder 10.2 AR CYP19A1
13 hypospadias 10.2 AR SRD5A1 SRD5A2
14 withdrawal disorder 10.1 AR KLK3
15 corticosteroid-binding globulin deficiency 10.1 HP PPARG SERPINA6
16 androgen insensitivity, partial 10.1 AR CYP19A1 SRD5A1
17 androgenic alopecia 10.1 AR CYP19A1 KLK3
18 gynecomastia 10.1 AR CYP19A1 KLK3
19 reproductive system disease 10.1 AR CYP19A1 KLK3
20 endometrial disease 10.1 CYP19A1 HP
21 complete androgen insensitivity syndrome 10.0 AR CYP19A1 NR1H2
22 nephrogenic adenoma 10.0 AMACR KLK3
23 urethra adenocarcinoma 10.0 AMACR KLK3
24 pseudohermaphroditism 10.0 AR CYP19A1 SRD5A2
25 urethra clear cell adenocarcinoma 10.0 AMACR KLK3
26 breast cyst 10.0 KLK3 SERPINA3
27 urethral benign neoplasm 10.0 AMACR KLK3
28 endometriosis of ovary 9.9 AKR1C3 CYP19A1
29 urethral diverticulum 9.9 AMACR KLK3
30 prostatic acinar adenocarcinoma 9.9 AMACR AR KLK3
31 alopecia, androgenetic, 1 9.8 AR CYP19A1 SRD5A1 SRD5A2
32 aromatase excess syndrome 9.8 AMACR CYP19A1
33 aging 9.8
34 sex differentiation disease 9.8 AR CYP19A1
35 suppression of tumorigenicity 12 9.7 AMACR AR FOLH1 KLK3
36 male reproductive organ cancer 9.7 AMACR AR FOLH1 KLK3
37 reproductive organ cancer 9.7 AMACR AR FOLH1 KLK3
38 insulin-like growth factor i 9.6
39 body mass index quantitative trait locus 11 9.6
40 body mass index quantitative trait locus 9 9.6
41 body mass index quantitative trait locus 8 9.6
42 body mass index quantitative trait locus 4 9.6
43 body mass index quantitative trait locus 10 9.6
44 body mass index quantitative trait locus 7 9.6
45 body mass index quantitative trait locus 12 9.6
46 body mass index quantitative trait locus 14 9.6
47 body mass index quantitative trait locus 18 9.6
48 surfactant metabolism dysfunction, pulmonary, 1 9.4
49 surfactant metabolism dysfunction, pulmonary, 4 9.4
50 myocardial infarction 9.4

Comorbidity relations with Prostate Disease via Phenotypic Disease Network (PDN):


Prostate Cancer Prostatic Hypertrophy

Graphical network of the top 20 diseases related to Prostate Disease:



Diseases related to Prostate Disease

Symptoms & Phenotypes for Prostate Disease

UMLS symptoms related to Prostate Disease:


equilibration disorder, prostatism, tremor, angina pectoris

MGI Mouse Phenotypes related to Prostate Disease:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.96 GADD45A HBEGF HP NR1H2 PPARG AKR1C3
2 endocrine/exocrine gland MP:0005379 9.87 GADD45A NR1H2 PPARG SRD5A1 AR SRD5A2
3 liver/biliary system MP:0005370 9.7 HP NR1H2 PPARG AMACR SERPINA6 AR
4 renal/urinary system MP:0005367 9.43 GADD45A HP PPARG SERPINA6 AR CYP19A1
5 reproductive system MP:0005389 9.23 NR1H2 PPARG AKR1C3 AR SRD5A1 SRD5A2

Drugs & Therapeutics for Prostate Disease

Drugs for Prostate Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 825)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iodine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 7553-56-2 807
2
Povidone Approved Phase 4 9003-39-8
3
Povidone-iodine Approved Phase 4 25655-41-8
4
Tamsulosin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 106133-20-4 129211
5
Bupivacaine Approved, Investigational Phase 4,Phase 1,Phase 2 38396-39-3, 2180-92-9 2474
6
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
7
Dutasteride Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 164656-23-9 6918296 152945
8
Finasteride Approved Phase 4,Phase 3,Phase 2,Phase 1 98319-26-7 57363
9
Ethanol Approved Phase 4,Phase 2,Phase 1 64-17-5 702
10
Fesoterodine Approved Phase 4 286930-02-7, 286930-03-8 6918558
11
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1 657-24-9 4091 14219
12
Goserelin Approved Phase 4,Phase 3,Phase 2,Phase 1 65807-02-5 5311128 47725
13
Doxazosin Approved Phase 4,Phase 3,Phase 2 74191-85-8 3157
14
Alfuzosin Approved, Investigational Phase 4,Phase 3,Phase 2 81403-80-7 2092
15
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-22-0 6013
16
Tadalafil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 171596-29-5 110635
17
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1 58-18-4 6010
18
Menthol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 2216-51-5 16666
19
Histamine Approved, Investigational Phase 4,Phase 2,Early Phase 1 51-45-6, 75614-87-8 774
20
Lenograstim Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 135968-09-1
21
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
22
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
23
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
24
Leuprolide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53714-56-0 657181 3911
25
Bicalutamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 90357-06-5 2375 56069
26
Zoledronic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 118072-93-8 68740
27
Acetaminophen Approved Phase 4,Phase 2,Phase 1 103-90-2 1983
28
Flutamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 13311-84-7 3397
29
Somatostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
30
Celecoxib Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 169590-42-5 2662
31
Ciprofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2 85721-33-1 2764
32
Terazosin Approved Phase 4 63590-64-7 5401
33
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
34
Silodosin Approved Phase 4,Phase 3,Phase 2 160970-54-7
35
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
36
Lidocaine Approved, Vet_approved Phase 4,Phase 2 137-58-6 3676
37
Dihydrotachysterol Approved Phase 4,Phase 2 67-96-9 5311071 5281010
38
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
39
Mepivacaine Approved, Vet_approved Phase 4 96-88-8 4062
40
Midazolam Approved, Illicit Phase 4,Phase 1 59467-70-8 4192
41
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
42
Diphenhydramine Approved, Investigational Phase 4,Phase 2,Phase 1 58-73-1, 147-24-0 3100
43
Dopamine Approved Phase 4,Phase 2 51-61-6, 62-31-7 681
44
Granisetron Approved, Investigational Phase 4 109889-09-0 3510
45
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
46
Ondansetron Approved Phase 4 99614-02-5 4595
47
Promethazine Approved, Investigational Phase 4,Phase 2,Phase 1 60-87-7 4927
48
Ranitidine Approved Phase 4,Phase 2 66357-59-3, 66357-35-5 3001055
49
Etidronic acid Approved Phase 4,Phase 3 2809-21-4, 7414-83-7 3305
50 Mirabegron Approved Phase 4 223673-61-8

Interventional clinical trials:

(show top 50) (show all 3847)

# Name Status NCT ID Phase Drugs
1 A Prospective Trial of Povidone-iodine Suppository Before Transrectal Ultrasound Guided Prostate Biopsy Unknown status NCT02245334 Phase 4 Povidone-Iodine
2 Efficacy and Safety of Naftopidil in Patient With Neurogenic Lower Urinary Tract Dysfunction Not Caused by Benign Prostatic Hyperplasia Unknown status NCT02034604 Phase 4 Naftofidil;Tamsulosin
3 Low Dose Bupivacaine Spinal for Trans Uretral Prostatectomy. Unknown status NCT01861041 Phase 4 Heavy Bupivacaine;Isobaric Bupivacaine
4 Comparison Between Alpha Blocker Monotherapy and 5ARI Monotherapy Following Combination Therapy in Benign Prostatic Hyperplasia (BPH) Unknown status NCT01301599 Phase 4 combination therapy;alpha blocker monotherapy;5 alpha reductase inhibitor monotherapy
5 A Study Comparing Photoselective Vaporization of the Prostate With the GreenLight XPS™ Laser System and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Hyperplasia Unknown status NCT01218672 Phase 4
6 Clinical Study to Assess the Influence of a Saw Palmetto Preparation in Patients With Benign Prostatic Hyperplasia (BPH) and Sexual Dysfunctions Unknown status NCT01021267 Phase 4 Saw palmetto berry extract
7 A Study to Determine the Improvement of the Symptoms of Benign Prostatic Hyperplasia (BPH) When Switching Subjects From Proscar to Avodart Unknown status NCT00690950 Phase 4 Dutasteride
8 Kinetics of the Finasteride Prostate Induced Apoptosis Unknown status NCT00130767 Phase 4 finasteride
9 Prostatic Artery Embolization Versus 532 nm Green Light PVP for Catheterized Patients Unknown status NCT02006303 Phase 4
10 Advanced Benefits of Alpha-blocker Monotherapy on Lower Urinary Tracts Symptoms(LUTS) Patients Unknown status NCT01736033 Phase 4 Tamsulosin;Finasteride;Placebo
11 An Open Label Study to Measure Efficacy of Fesoterodine (Toviaz) Post Surgery for Benign Prostatic Hyperplasia Unknown status NCT00605319 Phase 4 Toviaz (Fesoterodine)
12 Metformin And Longevity Unknown status NCT02511665 Phase 4 Metformin;Placebo
13 Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy Unknown status NCT01379742 Phase 4
14 Treatment of Localized Prostate Cancer With High Intensity Focused Ultrasound Using the Sonablate® 500 System in Canada Unknown status NCT00573586 Phase 4
15 FINNPROSTATE Study VII: Intermittent Versus Continuous Androgen Deprivation in Patients With Advanced Prostate Cancer Unknown status NCT00293670 Phase 4 Goserelin (Zoladex)
16 Trial of HoLEP vs. PVP in Treating BPH in Patients With Bleeding Tendency Unknown status NCT02293759 Phase 4
17 Clasic Laryngeal Mask Airway(C-LMA) and I-gel Releated Regurgitation and Complications Unknown status NCT01876836 Phase 4
18 Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer Unknown status NCT00906269 Phase 4 Sildenafil therapy plus post-NSRRP HBO2T;Sildenafil therapy plus sham post-NSRRP HBO2T
19 Combination Treatment With Doxazosin Plus TolterodineSR 2 mg Versus 4mg in Men With an Overactive Bladder (OAB) and Benign Prostatic Hyperplasia (BPH) Unknown status NCT00922506 Phase 4 doxazosin plus tolterodine SR
20 Early Detection of Prostate Cancer by FACS Unknown status NCT00524823 Phase 4
21 MR-Lymphography and Lymph Node Staging in Prostate Cancer Unknown status NCT00185029 Phase 4
22 Alfuzosin XL Lower Urinary Tract Symptoms Efficacy and Sexuality Study Completed NCT00575913 Phase 4 Alfuzosin
23 Treatment of Chronic Bacterial Prostatitis Completed NCT02130713 Phase 4 Third generation fluoroquinolone
24 Evaluation Of The Efficacy And Safety Of The Doxasozin Gastrointestinal Therapeutic System (GITS) In Patients With Prostate Enlargement Completed NCT00648323 Phase 4 Doxazosin mysylate GITS
25 Benign Prostatic Hyperplasia (BPH) Screening Tool Case Finding Study in Subjects >=50 Years Completed NCT02757963 Phase 4
26 A Trial Assessing Peri-procedure Chemoprophylaxis During Transrectal Prostate Needle Biopsy Completed NCT02423759 Phase 4 ciprofloxacin;ciprofloxacin and gentamycine;culture based chemoprophylaxis
27 FLOMAX® Versus HYTRIN® in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia Completed NCT02244255 Phase 4 FLOMAX® capsules;Ascending doses of HYTRIN® capsules
28 Study to Evaluate the Symptomatic Relief Effects of FLOMAX® in Patients With Signs and Symptoms of Benign Prostatic Hyperplasia Completed NCT02244242 Phase 4 Tamsulosin hydrochloride
29 Study to Evaluate the Therapeutic Action of Tamsulosin and Finasteride in Symptomatic Benign Prostatic Hyperplasia (BPH) Patients Completed NCT02244229 Phase 4 Tamsulosin;Finasteride;Placebo
30 KTP Green Light Prostatectomy Compared With Open Prostatectomy Completed NCT02072499 Phase 4
31 Assessment of Prostatic Tissue Concentration of Ertapenem After a Pre-operative Administration Completed NCT02041767 Phase 4 Ertapenem
32 Prospective Sexual Function Study for BPH Subjects Completed NCT01777269 Phase 4 Dutasteride plus tamsulosin;Placebo
33 Effectiveness and Safety of Silodosin in the Treatment of Benign Prostatic Hyperplasia Completed NCT01757769 Phase 4 Silodosin
34 Addition of Lidocaine to Levobupivacaine Reduces Intrathecal Block Duration Completed NCT01675895 Phase 4 Levobupivacaine lidocaine spinal anesthesia;levobupivacaine Spinal anesthesia
35 Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia) Completed NCT01604811 Phase 4 Permixon® 160 mg;Tamsulosine Arrow LP;Placebo matching Permixon® 160 mg;Placebo matching Tamsulosine Arrow LP
36 Phase 4 Study of Greenlight XPS Laser Versus BiVAP Saline Vaporization of the Prostate in Men With Symptomatic Benign Prostatic Hyperplasia Completed NCT01500057 Phase 4
37 Holmium Laser Enucleation of Prostate(HOLEP) vs Greenlight(XPS) Laser Photoselective Vapo-Enucleation of Prostate(PVEP) Completed NCT01494337 Phase 4
38 Study of a α1A Adrenoceptor Selective Antagonist Silodosin to Treat Severe Benign Prostatic Hyperplasia(BPH) Completed NCT01259531 Phase 4 Silodosin
39 Effect of Dutasteride on HIF-1alpha and VEGF in the Prostate Completed NCT00880672 Phase 4 dutasteride
40 Dutasteride and Flex Dose of Tamsulosin on as Needed Basis, to Treat Benign Prostatic Hyperplasia Completed NCT00701779 Phase 4 Tamsulosin
41 Once Daily Given Alfuzosin in the Treatment of BPH Completed NCT00637715 Phase 4 Alfuzosin
42 SAMBA: Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin Completed NCT00486785 Phase 4 Alfuzosin
43 A Long-Term Study Examining the Treatment of Benign Prostatic Hyperplasia With Photoselective Vaporization Completed NCT00465101 Phase 4
44 Male Sexual Health Questionnaire (MSHQ) - Sexual Function Study Completed NCT00427882 Phase 4 ALFUZOSIN
45 Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin Completed NCT00401661 Phase 4 Alfuzosin
46 A Prospective Evaluation of the GreenLight Model 120 Laser Completed NCT00364585 Phase 4
47 ALF-ONE : ALFuzosin ONcE Daily Completed NCT00280605 Phase 4 Alfuzosin
48 Bipolar vs Monopolar Transurethral Resection of the Prostate (TURP) Completed NCT00199550 Phase 4
49 Effect Of Dutasteride On Intraprostatic Dihydrotestosterone (DHT) Levels Completed NCT00062790 Phase 4 Dutasteride
50 Comparative Efficacy of Dutasteride Plus Tamulosin With Lifestyle Advice Versus Watchful Waiting Plus Lifestyle Advice in the Management of Treatment naïve Men With Moderately Symptomatic Benign Prostatic Hyperplasia and Prostate Enlargement Completed NCT01294592 Phase 4 Dutasteride plus tamsulosin;tamsulosin

Search NIH Clinical Center for Prostate Disease

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: prostatic diseases

Genetic Tests for Prostate Disease

Anatomical Context for Prostate Disease

MalaCards organs/tissues related to Prostate Disease:

38
Prostate, Bone, Breast, Testes, Lymph Node, Lung, T Cells

Publications for Prostate Disease

Articles related to Prostate Disease:

(show top 50) (show all 175)
# Title Authors Year
1
Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives. ( 29335762 )
2018
2
Association between male pattern baldness and prostate disease: A meta-analysis. ( 29054497 )
2018
3
Re: Evolution of Primary Care Referrals to Urology. Impact of a Protocol on Prostate Disease and Continuing Education. ( 29144897 )
2017
4
Over-Expression of Activin-I^C Is Associated with Murine and Human Prostate Disease. ( 28116672 )
2017
5
Dynamic instrumented palpation - a new method for soft tissue quality assessment: application to prostate disease diagnosis. ( 28965477 )
2017
6
Re: Testosterone Replacement Therapy on the Natural History of Prostate Disease. ( 27845125 )
2016
7
Erratum: Comparative study of serum zinc concentrations in benign and malignant prostate disease: A Systematic Review and Meta-Analysis. ( 27436144 )
2016
8
Comparative study of serum zinc concentrations in benign and malignant prostate disease: A Systematic Review and Meta-Analysis. ( 27170414 )
2016
9
Serum GADD45a methylation is a useful biomarker to distinguish benign vs malignant prostate disease. ( 26171936 )
2015
10
The investigation of GSTP1, APC and RASSF1 gene promoter hypermethylation in urine DNA of prostate-diseased patients. ( 25665470 )
2015
11
Testosterone Replacement Therapy on the Natural History of Prostate Disease. ( 26077355 )
2015
12
Further evaluation of uPA and PAI-1 as biomarkers for prostatic diseases. ( 25323935 )
2015
13
Prostatectomy for benign prostate disease: open, laparoscopic and robotic techniques. ( 26497345 )
2015
14
Initial Evaluation of the Safety of Nanoshell-Directed Photothermal Therapy in the Treatment of Prostate Disease. ( 26296672 )
2015
15
Configuration and validation of a novel prostate disease nomogram predicting prostate biopsy outcome: A prospective study correlating clinical indicators among Filipino adult males with elevated PSA level. ( 29264129 )
2015
16
MALDI MS profiling of post-DRE urine samples highlights the potential of I^-microseminoprotein as a marker for prostatic diseases. ( 24115268 )
2014
17
Lycopene for the prevention and treatment of prostate disease. ( 24531784 )
2014
18
Evolution of primary care referrals to urology. Impact of a protocol on prostate disease and continuing education. ( 25554605 )
2014
19
Androgens and prostate disease. ( 24407178 )
2013
20
Seminal plasma glycoproteins in male infertility and prostate diseases: is there a chance for glyco-biomarkers? ( 23061682 )
2013
21
Serum amyloid A, phospholipase Aa88-IIA and C-reactive protein as inflammatory biomarkers for prostate diseases. ( 24061501 )
2013
22
Current status of 5I+-reductase inhibitors in prostate disease management. ( 23614056 )
2013
23
Effect of microbubble-enhanced ultrasound on prostate permeability: a potential therapeutic method for prostate disease. ( 23414693 )
2013
24
Circulating Prostate Cells Found in Men with Benign Prostate Disease Are P504S Negative: Clinical Implications. ( 23690774 )
2013
25
Aromatase up-regulation, insulin and raised intracellular oestrogens in men, induce adiposity, metabolic syndrome and prostate disease, via aberrant ER-I+ and GPER signalling. ( 22233684 )
2012
26
Patient reported incontinence after radical prostatectomy is more common than expected and not associated with the nerve sparing technique: results from the Center for Prostate Disease Research (CPDR) database. ( 21826727 )
2012
27
Prostate disease risk factors among a New Zealand cohort. ( 23363810 )
2012
28
Can a Gleason 6 or Less Microfocus of Prostate Cancer in One Biopsy and Prostate-Specific Antigen Level <10a88ng/mL Be Defined as the Archetype of Low-Risk Prostate Disease? ( 22848218 )
2012
29
Botulinum toxin A in prostate disease: a venom from bench to bed-side. ( 22409179 )
2012
30
Treatment for prostate disease should be uniform across the UK. ( 27794764 )
2012
31
Correlation between age and Chromogranin A determination in prostate diseases. ( 22674297 )
2011
32
Cholesterol and benign prostate disease. ( 21862201 )
2011
33
Risk of prostate cancer associated with benign prostate disease: a primary care case-control study. ( 22054323 )
2011
34
Detecting gene-gene interactions in prostate disease in African American men. ( 21992608 )
2011
35
Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database. ( 21091976 )
2011
36
Long-term effects of dihydrotestosterone treatment on prostate growth in healthy, middle-aged men without prostate disease: a randomized, placebo-controlled trial. ( 21079217 )
2010
37
ACR appropriateness criteria on obstructive voiding symptoms secondary to prostate disease. ( 20362939 )
2010
38
The role of oestrogen in the pathogenesis of obesity, type 2 diabetes, breast cancer and prostate disease. ( 20535861 )
2010
39
N-glycosylation status of beta-haptoglobin in sera of patients with prostate cancer vs. benign prostate diseases. ( 19956848 )
2010
40
Serum free circulating DNA is a useful biomarker to distinguish benign versus malignant prostate disease. ( 20647404 )
2010
41
High-fat diet, obesity and prostate disease: the ATX-LPA axis? ( 19204739 )
2009
42
Evaluation of ischemia-modified albumin in myocardial infarction and prostatic diseases. ( 19375269 )
2009
43
Serum CXCL13 positively correlates with prostatic disease, prostate-specific antigen and mediates prostate cancer cell invasion, integrin clustering and cell adhesion. ( 19375853 )
2009
44
Clinical guidelines: should 5 alpha-reductase inhibitors be used for prostate disease? ( 19578352 )
2009
45
5alpha-Reductase inhibitor treatment of prostatic diseases: background and practical implications. ( 19030020 )
2009
46
A broader role for 5ARIs in prostate disease? Existing evidence and emerging benefits. ( 19267353 )
2009
47
The Center for Prostate Disease Research (CPDR): a multidisciplinary approach to translational research. ( 19720304 )
2009
48
A new vision for the study of benign prostate disease: the NIDDK Prostate Research Strategic Plan. ( 19150562 )
2009
49
Serum active hepatocyte growth factor (AHGF) in benign prostatic disease and prostate cancer. ( 19021204 )
2009
50
PROBE: patient and physician behaviour and education in prostate disease. ( 18173808 )
2008

Variations for Prostate Disease

Expression for Prostate Disease

Search GEO for disease gene expression data for Prostate Disease.

Pathways for Prostate Disease

Pathways related to Prostate Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.68 AR GADD45A KLK3 PPARG SRD5A2
2 12.15 AMACR CYP19A1 NR1H2 PPARG
3 11.8 AR CYP19A1 GADD45A
4
Show member pathways
11.45 AR NR1H2 PPARG
5
Show member pathways
11.38 CYP19A1 SRD5A1 SRD5A2
6
Show member pathways
11.19 AR HBEGF KLK3 SRD5A1 SRD5A2
7
Show member pathways
11.07 AKR1C3 CYP19A1 SRD5A1 SRD5A2
8
Show member pathways
10.67 AKR1C3 SRD5A1 SRD5A2

GO Terms for Prostate Disease

Cellular components related to Prostate Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell body fiber GO:0070852 8.62 SRD5A1 SRD5A2

Biological processes related to Prostate Disease according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 transcription initiation from RNA polymerase II promoter GO:0006367 9.78 AR NR1H2 PPARG
2 response to organic cyclic compound GO:0014070 9.77 PPARG SRD5A1 SRD5A2
3 steroid metabolic process GO:0008202 9.75 AKR1C3 SRD5A1 SRD5A2
4 steroid biosynthetic process GO:0006694 9.69 CYP19A1 SRD5A1 SRD5A2
5 steroid hormone mediated signaling pathway GO:0043401 9.67 AR NR1H2 PPARG
6 male gonad development GO:0008584 9.67 AKR1C3 AR SRD5A1 SRD5A2
7 lipid homeostasis GO:0055088 9.61 NR1H2 PPARG
8 positive regulation of reactive oxygen species metabolic process GO:2000379 9.6 AKR1C3 GADD45A
9 male genitalia development GO:0030539 9.58 SRD5A1 SRD5A2
10 hypothalamus development GO:0021854 9.57 SRD5A1 SRD5A2
11 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.56 NR1H2 PPARG
12 androgen biosynthetic process GO:0006702 9.55 SRD5A1 SRD5A2
13 cellular response to testosterone stimulus GO:0071394 9.54 AR SRD5A1
14 prostate gland growth GO:0060736 9.52 AR CYP19A1
15 sex differentiation GO:0007548 9.5 AR SRD5A1 SRD5A2
16 negative regulation of cholesterol storage GO:0010887 9.48 NR1H2 PPARG
17 response to follicle-stimulating hormone GO:0032354 9.46 SRD5A1 SRD5A2
18 negative regulation of interferon-gamma-mediated signaling pathway GO:0060336 9.43 NR1H2 PPARG
19 androgen metabolic process GO:0008209 9.43 CYP19A1 SRD5A1 SRD5A2
20 cellular response to prostaglandin stimulus GO:0071379 9.4 AKR1C3 PPARG
21 progesterone metabolic process GO:0042448 9.33 AKR1C3 SRD5A1 SRD5A2
22 female genitalia development GO:0030540 9.13 CYP19A1 SRD5A1 SRD5A2
23 testosterone biosynthetic process GO:0061370 8.8 AKR1C3 CYP19A1 SRD5A2

Molecular functions related to Prostate Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 steroid hormone receptor activity GO:0003707 9.5 AR NR1H2 PPARG
2 steroid binding GO:0005496 9.43 AR SERPINA6
3 nuclear receptor activity GO:0004879 9.43 AR NR1H2 PPARG
4 oxidoreductase activity, acting on the CH-CH group of donors GO:0016627 9.4 SRD5A1 SRD5A2
5 retinoid X receptor binding GO:0046965 9.37 NR1H2 PPARG
6 amide binding GO:0033218 9.16 SRD5A1 SRD5A2
7 cholestenone 5-alpha-reductase activity GO:0047751 8.96 SRD5A1 SRD5A2
8 3-oxo-5-alpha-steroid 4-dehydrogenase activity GO:0003865 8.62 SRD5A1 SRD5A2

Sources for Prostate Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....